|
| 37730089 | Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study. | J Allergy Clin Immunol Pract | 2024 |
| 38009241 | A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. | Allergy | 2024 |
| 36868261 | Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 |
| 38082409 | Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis. | Allergy Asthma Clin Immunol | 2023 |
| 37746795 | Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat. | Clin Transl Allergy | 2023 |
| 37028510 | Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. | Ann Allergy Asthma Immunol | 2023 |
| 36774155 | An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. | Lancet | 2023 |
| 34287942 | Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. | Allergy | 2022 |
| 35831891 | Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. | Allergy Asthma Clin Immunol | 2022 |
| 35497649 | The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. | World Allergy Organ J | 2022 |
| 36057583 | Correction: Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. | Allergy Asthma Clin Immunol | 2022 |
| 35944615 | Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease. | Vox Sang | 2022 |
| 35219377 | Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet | 2022 |
| 35294812 | Inhibition of Prekallikrein for Hereditary Angioedema. | N Engl J Med | 2022 |
| 34753535 | Evaluation of the ocular safety associated with the exhalation delivery system with fluticasone. | Allergy Asthma Proc | 2022 |
| 33098856 | Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: AÂ randomized, double-blind, placebo-controlled phase 3 trial. | J Allergy Clin Immunol | 2021 |
| 33866032 | Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). | J Allergy Clin Immunol Pract | 2021 |
| 34879971 | Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management. | Clin Ther | 2021 |
| 34176500 | Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy. | Allergy Asthma Clin Immunol | 2021 |
| 34112472 | Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema-Prevalence and Relevance. | J Allergy Clin Immunol Pract | 2021 |
| 34048855 | Consensus on treatment goals in hereditary angioedema: AÂ global Delphi initiative. | J Allergy Clin Immunol | 2021 |
| 34305948 | Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. | Front Immunol | 2021 |
| 33258114 | Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. | Allergy | 2021 |
| 32452549 | Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. | Allergy | 2020 |
| 33109318 | Hereditary angioedema: Epidemiology and burden of disease. | Allergy Asthma Proc | 2020 |
| 32248571 | Definition, aims, and implementation of GA<sup>2</sup> LEN/HAEi Angioedema Centers of Reference and Excellence. | Allergy | 2020 |
| 32534150 | Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey. | J Allergy Clin Immunol Pract | 2020 |
| 30660873 | Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. | J Allergy Clin Immunol Pract | 2019 |
| 31485239 | Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. | Allergy Asthma Clin Immunol | 2019 |
| 31621458 | Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study. | Immunotherapy | 2019 |
| 30772477 | Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. | J Allergy Clin Immunol Pract | 2019 |
| 31170541 | Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. | J Allergy Clin Immunol Pract | 2019 |
| 30682573 | Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. | J Allergy Clin Immunol Pract | 2019 |
| 30550806 | Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States. | J Allergy Clin Immunol Pract | 2019 |
| 30539362 | Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. | BioDrugs | 2019 |
| 29318628 | The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. | Allergy | 2018 |
| 29998524 | Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema. | Clin Exp Allergy | 2018 |
| 30132644 | Current and emerging therapies to prevent hereditary angioedema attacks. | Am J Manag Care | 2018 |
| 30056152 | Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. | Ann Allergy Asthma Immunol | 2018 |
| 30480729 | Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. | JAMA | 2018 |
| 30534402 | Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema. | Nurs Open | 2018 |
| 29503818 | Hereditary Angioedema: The Economics of Treatment of an Orphan Disease. | Front Med (Lausanne) | 2018 |
| 29391286 | Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. | J Allergy Clin Immunol Pract | 2018 |
| 29669666 | Hereditary angioedema from the patient's perspective: A follow-up patient survey. | Allergy Asthma Proc | 2018 |
| 29688579 | Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2Â study. | Allergy | 2018 |
| 27865714 | Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. | Ann Allergy Asthma Immunol | 2017 |
| 28225674 | Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. | N Engl J Med | 2017 |
| 28381322 | Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema. | Allergy Rhinol (Providence) | 2017 |
| 28328347 | Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. | N Engl J Med | 2017 |
| 28286153 | Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. | J Allergy Clin Immunol Pract | 2017 |